Suggestions
Michael Paas
Head, Global Market Access & Pricing at Regeneron Pharmaceuticals, Inc.
Professional Background
Michael Paas is a distinguished senior biopharmaceutical commercial executive with an impressive background in strategic consulting and leadership roles within the healthcare sector. With years of experience under his belt, Michael has demonstrated exemplary capabilities in driving market access and pricing strategies across the biopharmaceutical landscape. His career is characterized by a robust track record that spans a multitude of therapeutic areas, showcasing his versatility and depth of knowledge in both global and US healthcare systems.
Throughout his career, Michael has assumed critical leadership positions, including his tenure as Vice President and Head of Value and Access at AbbVie, where he played a pivotal role in managing value propositions for innovative therapies. Moreover, as Head of Global Market Access and Pricing at Regeneron Pharmaceuticals, he enhanced the company’s strategic approach to entering new markets and securing favorable pricing agreements, influencing the accessibility of vital medications worldwide. His extensive industry experience is complemented by his previous roles at Bristol-Myers Squibb and Gfk, where he guided strategic initiatives that embraced payer insights and market landscape assessments.
Michael's unique blend of operational expertise and strategic mindset has not only propelled his career but has also benefitted the organizations he has been part of in terms of product development and market sustainability. He has always been adept in navigating the complexities of reimbursement and pricing within the ever-evolving healthcare environment, making substantial contributions to the improvement of health policy structures across various regions.
Education and Achievements
Michael's academic background is foundational to his successful career. He earned his Master of Business Administration in International Business and Finance from Columbia Business School, where he honed his analytical and strategic thinking skills. His education continued with a Master of Public Health from the Columbia School of Public Health, grounding him with an understanding of the public health landscape that complements his biopharmaceutical expertise. Michael originally studied Biophysics at The Johns Hopkins University for his Bachelor of Arts, providing him with a solid scientific basis that enhances his insights into drug development and its impact on health systems.
In tandem with his educational achievements, Michael has cultivated a wealth of industry experience through various prominent organizations. His multifaceted roles in consulting and direct management have introduced him to vital sectors of the biopharmaceutical industry, allowing him to enhance his skill set in innovative agreements and risk-sharing mechanisms, which are crucial for navigating today’s complex market demands.
Notable Achievements
Michael Paas has made substantial contributions throughout his career, with significant achievements that demonstrate his leadership capabilities and domain expertise. His strategic involvement in the launch of pivotal therapies in oncology, immuno-oncology, and other therapeutic areas has been particularly noteworthy, directly influencing patient outcomes and market accessibility. Michael specializes in not just understanding pricing and reimbursement strategies, but also in crafting compelling value messages that resonate with diverse stakeholders in the healthcare space.
Moreover, Michael’s influence extends beyond corporate roles; he has provided advisory services on investment opportunities as an advisor at The Cavendish Impact Foundation, where he’s leveraged his expertise to inform decision-making processes related to healthcare investments. His entrepreneurial spirit as the owner of Crosslink Ventures showcases his dedication to promoting innovations within the life sciences sector, enabling market access for groundbreaking therapies that can enhance patient care.
Michael's broad expertise encompasses numerous therapeutic areas, including cardiovascular, respiratory, dermatology, neuroscience, virology, and infectious diseases. His strategic insight has been instrumental in assessing drug pipelines and advancing products through various market stages—from pre-launch activities to lifecycle management of existing brands. This comprehensive knowledge allows him to evaluate licensing opportunities effectively and inform due diligence processes, thereby enhancing organizational growth and sustainability in a competitive landscape.
Achievements